Organisation paid for research Program year 2025 Source: CMS Open Payments

Sundance Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$2,284,160

1,032 payments

Through program year 2025, Sundance Clinical Research is reported as receiving $2,284,160 in research payments, across 1,032 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $422,170 244
2024 Research $738,487 513
2023 Research $147,948 106
2022 Research $860,381 150
2021 Research $27,389 9
2020 Research $87,285 9
2019 Research $500 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $756,192 23 payments
  2. Seqirus USA Inc $727,238 799 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $717,398 37 payments
  4. Pfizer Inc. $45,344 50 payments
  5. Boehringer Ingelheim International GmbH $31,312 122 payments
  6. Boehringer Ingelheim Pharma GmbH & Co.KG $6,677 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1, Open-Label, Randomized, Parallel Group, Single-Dose Clinica $669,954 3 payments
  2. Obesity Long term safety in patients with CV risk $394,121 5 payments
  3. A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $353,532 146 payments
  4. The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older $338,183 325 payments
  5. A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. $134,571 241 payments
  6. Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults $119,566 16 payments
  7. A Phase 2b, Randomized, Observer-Blind, Antigen and Adjuvant Dose-Confirmation Clinical Study to Evaluate Safety and Immunogenicity of Different Formulations of MF59-Adjuvanted Quadrivalent Subunit Inactivated Cell-derived Influenza Vaccine (aQIVc) in Older Adults =50 Years of Age $89,615 165 payments
  8. A Phase 3, Open-Label, Randomized, Controlled, Multi Country Study to $71,770 17 payments
  9. Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults $30,551 47 payments
  10. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $16,139 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record